한글목차

항진균 치료 시장 규모는 예측 기간 동안 3.89%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 기생충 감염 증가와 면역 감염의 확대가 시장 성장에 크게 기여하고 있습니다.

지역별로는 북미가 2022년 40%가 넘는 점유율로 가장 큰 비중을 차지할 것으로 보입니다. 전염성 감염병 환자 수 증가가 점유율 확대의 한 요인으로 작용할 것으로 보입니다.

세계 항진균 치료(항진균 치료) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이와 예측, 각종 부문별/지역별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

• 개요
• 성장 촉진요인
• 성장 억제요인
• 기회

제5장 시장 요인 분석

• 밸류체인 분석
• Porter's Five Forces 모델
• COVID-19의 영향

제6장 세계의 항진균 치료 시장 : 약제 클래스별

• 개요
• AZOLES
• ECHINOCANDINS
• POLYENES
• ALLYLAMINES
• PYRIMIDINES
• 기타

제7장 세계의 항진균 치료 시장 : 투여 경로별

• 개요
• 경구
• 국소
• 비경구

제8장 세계의 항진균 치료 시장 : 적응증별

• 개요
• 피부 사상균증
• 아스페르길루스증
• 칸디다증
• 침윤성 칸디다증
• 칸디다 질염
• 구강/인후/식도 칸디다증
• 기타

제9장 세계의 항진균 치료 시장 : 병원체별

• 개요
• CANDIDA
• ASPERGILLUS
• CRYPTOCOCCUS
• COCCIDIOIDES IMMITIS.
• ZYGOMYCETES
• TRICHOPHYTON
• 기타

제10장 세계의 항진균 치료 시장 : 최종사용자별

• 개요
• 병원 및 진료소
• 피부과 클리닉
• 기타

제11장 세계의 항진균 치료 시장 : 지역별

• 개요
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제12장 경쟁 구도

• 개요
• 경쟁 벤치마킹
• 주요 성장 전략
• 개발수 주요 기업
• 주요 개발 분석
• 주요 전개와 성장 전략
• 주요 기업 재무 상황

제13장 기업 개요

• PFIZER INC
• MERCK KGAA
• GILEAD SCIENCES, INC
• BAYER AG
• CIPLA INC
• NOVARTIS AG
• SANOFI S.A.
• ABBOTT
• JOHNSON & JOHNSON SERVICES, INC
• GLAXOSMITHKLINE PLC

제14장 부록

영문목차

Market Overview

The Antifungal Treatment Market is expected to register a CAGR of 3.89% during the review period.

The rising rate of parasitic contaminations and the rising pervasiveness of immunological infections are emphatically adding to the market development.

Contagious diseases incorporate both foundational and shallow contaminations, including contaminations of the skin, eye, mouth, and vagina. Antifungal items with fungicidal movement are for the most part used to treat a wide cluster of illnesses, like competitor's foot, ringworm, and parasitic meningitis, brought about by contagious specialists.

Also, there are a few items accessible related with various courses of organization on the market for the treatment of contagious diseases, like oral and intravenous prescriptions, creams, splashes, shampoos, arrangements, pessaries, and infusions. Moreover, expanding dispatches of imaginative items is further fueling the development of the market. For example, in May 2022, Bayer AG (Germany) sent off a better than ever Canesten antifungal treatment arrangement in India. The product offering, which is accessible in powder and cream structures, has against parasitic properties that guide in the counteraction and treatment of skin contaminations. The antifungal cream gives alleviation from contamination, and the gentle steroid cream lessens the irritation because of disease.

Thus, the high accessibility of various courses of organization and the rising predominance of various sorts of contagious contaminations are encouraging market development.

Market Segmentation

The Antifungal Treatment Market is divided into drug classes, such as azoles, echinocandins, polyenes, allylamines, pyrimidines, and others.

Oral, topical, and parenteral are the categories into which the market is divided based on the mode of administration.

Dermatophytosis, aspergillosis, candidiasis, invasive candidiasis, vulvovaginal candidiasis, mouth/throat/esophageal candidiasis, and others are the segments of the market based on the indication.

The Antifungal Treatment Market is divided into categories based on pathogens, including zygomycetes, trichophyton, aspergillus, cryptococcus, and coccidioides immitis. Clinics for dermatology, hospitals & clinics, and other categories make up the end user market.

Regional Analysis

North America represented the biggest market portion of more than 40% in 2022 is attributable to different variables and one of them is expanding number of individuals with contagious contaminations. Also, market players are shaping methodologies to disseminate and sell antifungal medication in the US.

The Europe against contagious contamination market development is driven by significantly obtrusive parasitic diseases, which have been emphatically expanding since the last 10 years in the European nations. Also, patients with hematologic malignancies and hematopoietic cell relocate beneficiaries (HCT) are found to get obtrusive parasitic contaminations in the European populace.

The Asia-Pacific enemy of parasitic treatment market is the quickest developing region during the forecast time frame attributable to expanding contagious disease cases in Asian nations. In 2020, the Worldwide Activity for Parasitic Diseases (GAFFI) and Fudan College (Shanghai) assessed that 1,000,000 individuals experience the ill effects of obtrusive aspergillosis in China every year.

Major Players

Key Companies in the Antifungal Treatment Market includes Pfizer Inc (US), Johnson & Johnson Services, Inc (US), Bayer AG (Germany), Novartis AG (Switzerland), Abbott Laboraotories, Inc. (US), Merck KGaA (Germany), Gilead Sciences, Inc (US), Cipla, Inc. (India), Sanofi S.A. (France), and GlaxoSmithKline Plc (UK).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENTS OF FUNGAL INFECTIONS
  • 4.2.2 INCREASING PREVALENCE OF IMMUNOLOGICAL DISEASES
  • 4.2.3 AVAILABILITY OF A WIDE RANGE OF PRODUCTS
• 4.3 RESTRAINTS
  • 4.3.1 SIDE-EFFECTS OF TREATMENT
• 4.4 OPPORTUNITIES
  • 4.4.1 DEVELOPMENT OF NEW DRUGS

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL ANTI-FUNGAL TREATMENT MARKET
  • 5.3.1 IMPACT ON MAKET GROWTH
  • 5.3.2 IMPACT ON SUPPLY CHAIN
  • 5.3.3 IMPACT ON DIAGNOSTICS AND TESTING
  • 5.3.4 CHANGES IN HEALTHCARE PRIORITIES
  • 5.3.5 IMPACT ON CLINICAL TRIALS

6 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS

• 6.1 OVERVIEW
• 6.2 AZOLES
• 6.3 ECHINOCANDINS
• 6.4 POLYENES
• 6.5 ALLYLAMINES
• 6.6 PYRIMIDINES
• 6.7 OTHERS

7 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

• 7.1 OVERVIEW
• 7.2 ORAL
• 7.3 TOPICAL
• 7.4 PARENTERAL

8 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION

• 8.1 OVERVIEW
• 8.2 DERMATOPHYTOSIS
• 8.3 ASPERGILLOSIS
• 8.4 CANDIDIASIS.
• 8.5 INVASIVE CANDIDIASIS.
• 8.6 VULVOVAGINAL CANDIDIASIS
• 8.7 MOUTH/THROAT/ESOPHAGEAL CANDIDIASIS
• 8.8 OTHERS

9 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS

• 9.1 OVERVIEW
• 9.2 CANDIDA
• 9.3 ASPERGILLUS
• 9.4 CRYPTOCOCCUS
• 9.5 COCCIDIOIDES IMMITIS.
• 9.6 ZYGOMYCETES
• 9.7 TRICHOPHYTON
• 9.8 OTHERS

10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER

• 10.1 OVERVIEW
• 10.2 HOSPITAL AND CLINICS
• 10.3 DERMATOLOGICAL CLINICS
• 10.4 OTHERS

11 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 US
  • 11.2.2 CANADA
• 11.3 EUROPE
  • 11.3.1 GERMANY
  • 11.3.2 FRANCE
  • 11.3.3 UK
  • 11.3.4 ITALY
  • 11.3.5 SPAIN
  • 11.3.6 SWITZERLAND
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA-PACIFIC
  • 11.4.1 CHINA
  • 11.4.2 INDIA
  • 11.4.3 JAPAN
  • 11.4.4 SOUTH KOREA
  • 11.4.5 AUSTRALIA
  • 11.4.6 REST OF ASIA-PACIFIC
• 11.5 REST OF THE WORLD
  • 11.5.1 MIDDLE EAST
  • 11.5.2 AFRICA
  • 11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 COMPETITIVE BENCHMARKING
• 12.3 MAJOR GROWTH STRATEGY IN THE ANTI-FUNGAL TREATMENT MARKET
• 12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE ANTI-FUNGAL TREATMENT MARKET
• 12.5 KEY DEVELOPMENT ANALYSIS
• 12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 12.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • 12.6.2 ACQUISITION
  • 12.6.3 AGREEMENT
  • 12.6.4 PARTNERSHIP
  • 12.6.5 EXPANSION
• 12.7 MAJOR PLAYERS FINANCIAL
  • 12.7.1 SALES (USD BILLION), 2022
  • 12.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD BILLION), 2022

13 COMPANY PROFILES

• 13.1 PFIZER INC
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCTS OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 MERCK KGAA
  • 13.2.1 COMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCTS OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 SWOT ANALYSIS
  • 13.2.6 KEY STRATEGIES
• 13.3 GILEAD SCIENCES, INC
  • 13.3.1 COMPANY OVERVIEWS
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCTS OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 KEY STRATEGIES
• 13.4 BAYER AG
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 KEY STRATEGIES
• 13.5 CIPLA INC
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCTS OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 KEY STRATEGIES
• 13.6 NOVARTIS AG
  • 13.6.1 COMPANY OVERVIEW
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 SWOT ANALYSIS
  • 13.6.6 KEY STRATEGIES
• 13.7 SANOFI S.A.
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 ABBOTT
  • 13.8.1 COMPANY OVERVIEW
  • 13.8.2 FINANCIAL OVERVIEW
  • 13.8.3 PRODUCTS OFFERED
  • 13.8.4 KEY DEVELOPMENTS
  • 13.8.5 KEY STRATEGIES
• 13.9 JOHNSON & JOHNSON SERVICES, INC
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCTS OFFERED
  • 13.9.4 KEY DEVELOPMENTS
  • 13.9.5 SWOT ANALYSIS
  • 13.9.6 KEY STRATEGIES
• 13.10 GLAXOSMITHKLINE PLC
  • 13.10.1 COMPANY OVERVIEW
  • 13.10.2 FINANCIAL OVERVIEW
  • 13.10.3 PRODUCTS OFFERED
  • 13.10.4 KEY DEVELOPMENTS
  • 13.10.5 KEY STRATEGIES

14 APPENDIX

• 14.1 REFERENCES
• 14.2 RELATED REPORTS